Science News
from research organizations

Preventing Lung Scarring May Extend Lives Of Lung Cancer Patients

Date:
October 31, 2007
Source:
American Society for Therapeutic Radiology and Oncology
Summary:
Researchers have found that using a special type of drug called a pharmaceutical monoclonal antibody to block the integrin beta6-TGF-beta pathway prevents a serious side effect of radiation therapy for lung cancer patients -- pulmonary fibrosis -- thereby extending patients' lives and improving their quality of life, according to a new study.
Share:
FULL STORY

Researchers have found that using a special type of drug called a pharmaceutical monoclonal antibody to block the integrin beta6-TGF-beta pathway prevents a serious side effect of radiation therapy for lung cancer patients -- pulmonary fibrosis (scarring of the lungs), thereby extending patients' lives and improving their quality of life, according to a new study.

"The toxicity of pulmonary fibrosis limits the amount of the radiation dose that can be safely given to patients," said Simon Cheng, M.D., Ph.D., an author of the study and a radiation oncologist at New York University Medical Center in New York. "These study results may lead to more effective radiation therapies for advanced lung cancer, which is the leading cause of cancer deaths in the U.S."

More than 50 percent of patients receiving radiation therapy for advanced lung cancer develop radiation-induced lung fibrosis, a painful side effect that can affect patients' quality of life and, in some cases, can be fatal. Pulmonary (lung) fibrosis involves inflammation and scarring of the lungs causing patients to feel short of breath, have a chronic dry cough, feel fatigue and pain in the chest, and suffer loss of appetite and weight loss. Over time, fibrosis causes the air sacs of the lungs to be replaced by scar tissue, causing difficulty breathing and an irreversible loss of the tissue's ability to transfer oxygen into the bloodstream.

This study involved mice treated with a 14 Gy single dose of radiation to the lungs. Researchers wanted to determine if using an antibody to block integrin beta6 (a specific activator of the transforming growth factor (TGF-beta) signaling pathway), could prevent the onset of radiation-induced pulmonary fibrosis. The study shows that mice that were given integrin beta6 monoclonal antibodies did not develop radiation-induced lung fibrosis, while the control group of mice developed the lung condition.

"Fibrosis is a very serious side effect that often keeps doctors from giving patients a full dose of radiation for fear that the serious problems caused by fibrosis will outweigh the good done by the radiation. If further studies conclude that this drug can indeed prevent fibrosis in lung cancer patients, I believe researchers are a huge step closer to curing this disease," said Dr. Cheng.

The abstract, "The Integrin-TGFbeta Axis: Inhibition of Integrin Alphav Beta6 Prevents Radiation-induced Lung Fibrosis," was presented at the Plenary I session on October 29, 2007, at the American Society for Therapeutic Radiology and Oncology's 49th Annual Meeting in Los Angeles on October 29, 2007. 


Story Source:

Materials provided by American Society for Therapeutic Radiology and Oncology. Note: Content may be edited for style and length.


Cite This Page:

American Society for Therapeutic Radiology and Oncology. "Preventing Lung Scarring May Extend Lives Of Lung Cancer Patients." ScienceDaily. ScienceDaily, 31 October 2007. <www.sciencedaily.com/releases/2007/10/071029121542.htm>.
American Society for Therapeutic Radiology and Oncology. (2007, October 31). Preventing Lung Scarring May Extend Lives Of Lung Cancer Patients. ScienceDaily. Retrieved May 28, 2017 from www.sciencedaily.com/releases/2007/10/071029121542.htm
American Society for Therapeutic Radiology and Oncology. "Preventing Lung Scarring May Extend Lives Of Lung Cancer Patients." ScienceDaily. www.sciencedaily.com/releases/2007/10/071029121542.htm (accessed May 28, 2017).

RELATED STORIES